A citation-based method for searching scientific literature

Sheldon Preskorn, Matthew Macaluso, D O Vishaal Mehra, Gary Zammit, Joseph R Moskal, Ronald M Burch. J Psychiatr Pract 2015
Times Cited: 132







List of co-cited articles
1549 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
60

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
57

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Nanxin Li, Boyoung Lee, Rong-Jian Liu, Mounira Banasr, Jason M Dwyer, Masaaki Iwata, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Science 2010
53

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Panos Zanos, Ruin Moaddel, Patrick J Morris, Polymnia Georgiou, Jonathan Fischell, Greg I Elmer, Manickavasagom Alkondon, Peixiong Yuan, Heather J Pribut, Nagendra S Singh,[...]. Nature 2016
873
47

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Jeffrey Burgdorf, Xiao-lei Zhang, Katherine L Nicholson, Robert L Balster, J David Leander, Patric K Stanton, Amanda L Gross, Roger A Kroes, Joseph R Moskal. Neuropsychopharmacology 2013
214
44


A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.
Lobna Ibrahim, Nancy Diaz Granados, Libby Jolkovsky, Nancy Brutsche, David A Luckenbaugh, W Joseph Herring, William Z Potter, Carlos A Zarate. J Clin Psychopharmacol 2012
151
34

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Anita E Autry, Megumi Adachi, Elena Nosyreva, Elisa S Na, Maarten F Los, Peng-fei Cheng, Ege T Kavalali, Lisa M Monteggia. Nature 2011
32

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects.
G Sanacora, M A Smith, S Pathak, H-L Su, P H Boeijinga, D J McCarthy, M C Quirk. Mol Psychiatry 2014
162
31

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.
Carlos A Zarate, Daniel Mathews, Lobna Ibrahim, Jose Franco Chaves, Craig Marquardt, Immaculata Ukoh, Libby Jolkovsky, Nancy E Brutsche, Mark A Smith, David A Luckenbaugh. Biol Psychiatry 2013
181
30

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.
Joseph R Moskal, Ronald Burch, Jeffrey S Burgdorf, Roger A Kroes, Patric K Stanton, John F Disterhoft, J David Leander. Expert Opin Investig Drugs 2014
93
31

The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.
J Burgdorf, X-L Zhang, C Weiss, A Gross, S R Boikess, R A Kroes, M A Khan, R M Burch, C S Rex, J F Disterhoft,[...]. Neuroscience 2015
57
49

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Sungho Maeng, Carlos A Zarate, Jing Du, Robert J Schloesser, Joseph McCammon, Guang Chen, Husseini K Manji. Biol Psychiatry 2008
843
27

A double-blind, placebo-controlled study of memantine in the treatment of major depression.
Carlos A Zarate, Jaskaran B Singh, Jorge A Quiroz, Georgette De Jesus, Kirk K Denicoff, David A Luckenbaugh, Husseini K Manji, Dennis S Charney. Am J Psychiatry 2006
295
26

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
Gerard Sanacora, Michael R Johnson, Arif Khan, Sarah D Atkinson, Robert R Riesenberg, Juan P Schronen, Michael A Burke, John M Zajecka, Luis Barra, Hong-Lin Su,[...]. Neuropsychopharmacology 2017
74
35

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Jaskaran B Singh, Maggie Fedgchin, Ella Daly, Liwen Xi, Caroline Melman, Geert De Bruecker, Andre Tadic, Pascal Sienaert, Frank Wiegand, Husseini Manji,[...]. Biol Psychiatry 2016
225
26

GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.
Rong-Jian Liu, Catharine Duman, Taro Kato, Brendan Hare, Dora Lopresto, Eunyoung Bang, Jeffery Burgdorf, Joseph Moskal, Jane Taylor, George Aghajanian,[...]. Neuropsychopharmacology 2017
75
34

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
James W Murrough, Dan V Iosifescu, Lee C Chang, Rayan K Al Jurdi, Charles E Green, Andrew M Perez, Syed Iqbal, Sarah Pillemer, Alexandra Foulkes, Asim Shah,[...]. Am J Psychiatry 2013
713
25

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Nancy Diazgranados, Lobna Ibrahim, Nancy E Brutsche, Andrew Newberg, Phillip Kronstein, Sami Khalife, William A Kammerer, Zenaide Quezado, David A Luckenbaugh, Giacomo Salvadore,[...]. Arch Gen Psychiatry 2010
671
25

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Madhukar H Trivedi, A John Rush, Stephen R Wisniewski, Andrew A Nierenberg, Diane Warden, Louise Ritz, Grayson Norquist, Robert H Howland, Barry Lebowitz, Patrick J McGrath,[...]. Am J Psychiatry 2006
25

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
D Jeffrey Newport, Linda L Carpenter, William M McDonald, James B Potash, Mauricio Tohen, Charles B Nemeroff. Am J Psychiatry 2015
359
25

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.
C Yang, Y Shirayama, J-c Zhang, Q Ren, W Yao, M Ma, C Dong, K Hashimoto. Transl Psychiatry 2015
336
25


Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Carlos A Zarate, Nancy E Brutsche, Lobna Ibrahim, Jose Franco-Chaves, Nancy Diazgranados, Anibal Cravchik, Jessica Selter, Craig A Marquardt, Victoria Liberty, David A Luckenbaugh. Biol Psychiatry 2012
514
24

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.
Uriel Heresco-Levy, Genia Gelfin, Boaz Bloch, Raz Levin, Shani Edelman, Daniel C Javitt, Ilana Kremer. Int J Neuropsychopharmacol 2013
112
24

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.
Nanxin Li, Rong-Jian Liu, Jason M Dwyer, Mounira Banasr, Boyoung Lee, Hyeon Son, Xiao-Yuan Li, George Aghajanian, Ronald S Duman. Biol Psychiatry 2011
753
24

The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.
Panos Zanos, Sean C Piantadosi, Hui-Qiu Wu, Heather J Pribut, Matthew J Dell, Adem Can, H Ralph Snodgrass, Carlos A Zarate, Robert Schwarcz, Todd D Gould. J Pharmacol Exp Ther 2015
79
29

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Ella J Daly, Jaskaran B Singh, Maggie Fedgchin, Kimberly Cooper, Pilar Lim, Richard C Shelton, Michael E Thase, Andrew Winokur, Luc Van Nueten, Husseini Manji,[...]. JAMA Psychiatry 2018
292
22

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
James W Murrough, Andrew M Perez, Sarah Pillemer, Jessica Stern, Michael K Parides, Marije aan het Rot, Katherine A Collins, Sanjay J Mathew, Dennis S Charney, Dan V Iosifescu. Biol Psychiatry 2013
479
21

The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.
Joseph R Moskal, Jeffrey S Burgdorf, Patric K Stanton, Roger A Kroes, John F Disterhoft, Ronald M Burch, M Amin Khan. Curr Neuropharmacol 2017
52
40

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Ronald S Duman, George K Aghajanian, Gerard Sanacora, John H Krystal. Nat Med 2016
761
21

BDNF release is required for the behavioral actions of ketamine.
Ashley E Lepack, Manabu Fuchikami, Jason M Dwyer, Mounira Banasr, Ronald S Duman. Int J Neuropsychopharmacol 2014
235
20

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Jaskaran B Singh, Maggie Fedgchin, Ella J Daly, Peter De Boer, Kimberly Cooper, Pilar Lim, Christine Pinter, James W Murrough, Gerard Sanacora, Richard C Shelton,[...]. Am J Psychiatry 2016
273
19

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.
Marije aan het Rot, Katherine A Collins, James W Murrough, Andrew M Perez, David L Reich, Dennis S Charney, Sanjay J Mathew. Biol Psychiatry 2010
450
18


Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Jorge A Quiroz, Paul Tamburri, Dennis Deptula, Ludger Banken, Ulrich Beyer, Michael Rabbia, Nikhat Parkar, Paulo Fontoura, Luca Santarelli. JAMA Psychiatry 2016
84
21

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.
Samuel T Wilkinson, Elizabeth D Ballard, Michael H Bloch, Sanjay J Mathew, James W Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A Zarate, Gerard Sanacora. Am J Psychiatry 2018
305
18

A randomized controlled trial of intranasal ketamine in major depressive disorder.
Kyle A B Lapidus, Cara F Levitch, Andrew M Perez, Jess W Brallier, Michael K Parides, Laili Soleimani, Adriana Feder, Dan V Iosifescu, Dennis S Charney, James W Murrough. Biol Psychiatry 2014
265
17



Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.
Chih-Chia Huang, I-Hua Wei, Chieh-Liang Huang, Kuang-Ti Chen, Mang-Hung Tsai, Priscilla Tsai, Rene Tun, Kuo-Hao Huang, Yue-Cune Chang, Hsien-Yuan Lane,[...]. Biol Psychiatry 2013
95
17

Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.
Rong-Jian Liu, Francis S Lee, Xiao-Yuan Li, Francis Bambico, Ronald S Duman, George K Aghajanian. Biol Psychiatry 2012
276
17

Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.
Bangkun Yang, Ji-Chun Zhang, Mei Han, Wei Yao, Chun Yang, Qian Ren, Min Ma, Qian-Xue Chen, Kenji Hashimoto. Psychopharmacology (Berl) 2016
70
24

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
A John Rush, Madhukar H Trivedi, Stephen R Wisniewski, Andrew A Nierenberg, Jonathan W Stewart, Diane Warden, George Niederehe, Michael E Thase, Philip W Lavori, Barry D Lebowitz,[...]. Am J Psychiatry 2006
17

Synaptic dysfunction in depression: potential therapeutic targets.
Ronald S Duman, George K Aghajanian. Science 2012
809
17


R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine.
Ji-Chun Zhang, Su-Xia Li, Kenji Hashimoto. Pharmacol Biochem Behav 2014
201
16

GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.
Joseph R Moskal, Amy G Kuo, Craig Weiss, Paul L Wood, Amy O'Connor Hanson, Stephen Kelso, Robert B Harris, John F Disterhoft. Neuropharmacology 2005
75
21

Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
Uriel Heresco-Levy, Daniel C Javitt, Yovgenia Gelfin, Elena Gorelik, Marina Bar, Monica Blanaru, Ilana Kremer. J Affect Disord 2006
67
23

Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.
Bhavya Voleti, Andrea Navarria, Rong-Jian Liu, Mounira Banasr, Nanxin Li, Rose Terwilliger, Gerard Sanacora, Tore Eid, George Aghajanian, Ronald S Duman. Biol Psychiatry 2013
189
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.